Polychronis Kemos

Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study

Clive Ballard, Carol Banister, Zunera Khan et al. · The Lancet Neurology · 2018 · 188 citations

Medicine, Pharmacology, Psychiatry +15

Periodontitis is associated with significant hepatic fibrosis in patients with non-alcoholic fatty liver disease

William Alazawi, Eduardo Bernabé, David Tai et al. · PLoS ONE · 2017 · 81 citations · Full text

Medicine, Periodontics, Hepatology +13

Malignancy and mortality in paediatric‐onset inflammatory bowel disease: a 3‐year prospective, multinational study from the paediatric <scp>IBD</scp> Porto group of <scp>ESPGHAN</scp>

Maria E. Joosse, M Aardoom, Polychronis Kemos et al. · Alimentary Pharmacology & Therapeutics · 2018 · 53 citations · Full text

Medicine, Oncology, Pediatrics +12

Correlation Between Bevacizumab Exposure and Survival in Patients with Metastatic Colorectal Cancer

Apostolos Papachristos, Polychronis Kemos, Haralabos P. Kalofonos et al. · The Oncologist · 2020 · 34 citations · Full text

Medicine, Oncology, Pharmacology +16

Non-invasive markers of liver fibrosis in fatty liver disease are unreliable in people of South Asian descent

Sampath De Silva, Wenhao Li, Polychronis Kemos et al. · Frontline Gastroenterology · 2017 · 31 citations · Full text

Medicine, Internal Medicine, Pathology +17